SignalXSignalX

CELC Celcuity Inc.

FY2024 10-K
Filed: Mar 31, 2025
Health Care
Services-Medical LaboratoriesSEC EDGAR
Celcuity Inc. Overview

Celcuity Inc. (CELC) filed its fiscal year 2024 10-K annual report with the SEC on Mar 31, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2024 10-K

Business Overview

  • • Core business: Clinical-stage biotech developing gedatolisib, a pan-PI3K/mTOR inhibitor targeting multiple solid tumors, primarily HR+/HER2- advanced breast and metastatic prostate cancer
  • • New emphasis: Initiation and enrollment updates for two Phase 3 trials (VIKTORIA-1 completed PIK3CA WT enrollment in Q4 2024; VIKTORIA-2 site activation in Q3 2024, first patient expected Q2 2025)
+3 more insights

Management Discussion & Analysis

  • • No revenue or profitability data disclosed in the provided text
  • • No segment performance information available
+3 more insights

Risk Factors

  • • FDA approval risk tied to VIKTORIA-1 trial topline data expected Q2 2025, crucial for gedatolisib market authorization
  • • Clinical trial site exposure: 200+ sites across North America, Europe, Latin America, Asia-Pacific for VIKTORIA-1 and VIKTORIA-2 trials
+3 more insights

Financial Summary
XBRL

Net Income

-$112M

ROE

-96.7%

Total Assets

$245M

EPS (Diluted)

$-2.83

Operating Cash Flow

-$83M

Source: XBRL data from Celcuity Inc. FY2024 10-K filing on SEC EDGAR. All figures in USD.

Get deeper insights on Celcuity Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available